PharmAust CEO's sayanora triggers stock plunge
Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
VER | Ann:FY24 - Half Year Report (Price Sensitive) | 14/12/23 | 0 | 212 | |||
|
|||||||
VER | Ann:2023 AGM Results (Price Sensitive) | 31/08/23 | 0 | 322 | |||
|
|||||||
VER | Ann:Annual Nominated Adviser Statement for 2023 - 2024 | 03/08/23 | 0 | 296 | |||
|
|||||||
VER | Ann:NSX Notice of Annual General Meeting (Price Sensitive) | 28/07/23 | 0 | 259 | |||
|
|||||||
VER | Ann:NSX Proxy Form (Price Sensitive) | 28/07/23 | 0 | 257 | |||
|
|||||||
VER | Ann:Change in Substantial Shareholder | 30/06/23 | 0 | 319 | |||
|
|||||||
VER | Ann:Annual Report (Price Sensitive) | 30/06/23 | 0 | 421 | |||
|
|||||||
VER | Ann:Initial Substantial Holding | 30/06/23 | 0 | 310 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |